首页> 外文期刊>Fundamental & clinical pharmacology. >DISOPYRAMIDE‐INDUCED HYPOGLYCEMIA: CASE REPORT AND REVIEW OF THE LITERATURE
【24h】

DISOPYRAMIDE‐INDUCED HYPOGLYCEMIA: CASE REPORT AND REVIEW OF THE LITERATURE

机译:DISOPYRAMIDE‐INDUCED HYPOGLYCEMIA: CASE REPORT AND REVIEW OF THE LITERATURE

获取原文
       

摘要

Summary—Disopyramide is a group I antiarrhythmic drug which is mainly used for the treatment of ventricular and supraventricular rhythm disturbances. Commonest side effects result from disopyramide's anticholinergic activity. Other side effects such as hypoglycemia have been reported less frequently. We report one observation of disopyramide induced hypoglycemia, and a review of the literature is presented.Including our observation, 14 cases (9 men and 5 women, aged from 41 to 88) have so far been reported. Doses of disopyramide ranged from 200 to 1 200 mg per day, administered from one day to one year. Symptomatology was mainly neurologic (12 patients) and two patients were clinically asymptomatic. The outcome was favorable in all but the 2 patients who died with persistent hypoglycemia after a single dose of 250 mg in one patient and after 400 mg daily during 4 days in the other (without stopping the drug). Renal function was markedly impaired in 9 patients, two of these patients being on a long term dialysis therapy. Blood levels of disopyramide were measured in 7 patients and ranged from 1 to 11.4 ng/ml. In five patients it was in the normal range (1–4 ng/ml). Three patients were rechallenged for disopyramide: hypoglycemia occured in all, without clinical symptoms in two of them. The main risk factors of disopyramide induced hypoglycemia are a preexisting chronic renal failure, advanced age, and malnutrition. In these patients normally non toxic disopyramide blood levels, as defined in normal subjects, seem to be inappropriately high. We suggest that in patients at risk, disopyramide blood levels should be maintained at the lower range of therapeutic level. The recommended daily dose is 400 mg/day. Thus, it appears appropriate not to exceed 2/3 of this dosage, and to be particularly caution when using this drug in patients at r

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号